Clearly, when anti-MDA5 antibodies were involved, some symptoms and serological indicators differed across CADM and CDM, becoming substantial, or even changing from “nothing” to “something.” This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.